Extrinsic regulators of epithelial tumor progression: Metalloproteinases

Current Opinion in Genetics and Development

Volumn 10, Issue 1, 2000, Pages 120-127

  Bergers, Gabriele ^a   Coussens, Lisa M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; GROWTH FACTOR; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; STROMELYSIN;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; GENE MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; STROMA; TUMOR GROWTH;

EID: 0033994361     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)00043-X     Document Type: Review

References (49)

1. Coussens L.M., Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 3:1996;895-904.
2. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:1997;439-442.
3. Lukashev M.E., Werb Z. ECM signaling: orchestrating cell behavior and misbehavior. Trends Cell Biol. 8:1998;437-441. This paper, together with [2], is an outstanding review describing new targets of proteinase action.
4. Rawlings N.D., Barrett A.J. Evolutionary families of metallopeptidases. Methods Enzymol. 248:1995;183-228.
5. Stöcker W., Grams F., Baumann U., Reinemer P., Gomis-Rüth F.X., McKay D.B., Bode W. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 4:1995;823-840.
6. Wolfsberg T.G., White J.M. ADAMs in fertilization and development. Dev Biol. 180:1996;389-401.
7. Black R.A., White J.M. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 10:1998;654-659.
8. ••].
9. ••].
10. Tang B.L., Hong W. ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. 445:1999;223-225. A short review describing and characterizing the structural homology of four ADAMTS and three adamylisin-related proteinases.
11. Naik P., Christofori G., Hanahan D. Insulin-like growth factor II is focally upregulated and functionally involved as a second signal for oncogene-induced tumorigenesis. Cold Spring Harbor Symp Quant Biol. 59:1994;459-470.
12. Martin D.C., Fowlkes J.L., Babic B., Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol. 146:1999;881-892. An elegant in vivo study showing that regulation of hepatic tumor growth by IGF II is dependent on the balance of MMPs and their TIMP inhibitors. Degradation of IGF-binding proteins results in bioavailability of IGF II and IGF-I receptor signaling that is blocked by TIMP-1. These data indicate that IGF bioavailability is subject to control by MMP-mediated degradation of IGF-binding proteins.
13. Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine. 7:1997;111-113.
14. Fowlkes J.L., Enghild J.J., Suzuki K., Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem. 269:1994;25742-25746.
15. Mañes S., Mira E., del Mar Barbacid M., Ciprés A., Fernández-Resa P., María Buesa J., Mérida I., Aracil M., Márquez G., Martínez A.C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 272:1997;25706-25712.
16. Mañes S., Llorente M., Lacalle R.A., Gómez-Moutón C., Kremer L., Mira E., Martínez -A.C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 274:1999;6935-6945.
17. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
18. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood A.P. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 271:1996;10079-10086.
19. Czubayko F., Liaudet-Coopman E.D.E., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature. 3:1997;1137-1140.
20. Arribas J., Coodly L., Vollmer P., Kishimoto T.K., Rose-John S., Massagué J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem. 271:1996;11376-11382.
21. Tracey K., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 9:1993;317-443.
22. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1999;1382-1397. The authors demonstrate in a transgenic mouse model of squamous cell carcinogenesis that angiogenesis is regulated in a biphasic stage-specific manner by inflammatory host cells and tumor cells. In the first phase, mast cells potentiate an early angiogenic response in hyperplastic/dysplastic tissue by expressing enzymes that are implicated in stromal remodeling and neovascularization. At the tumor stage, cancers are deprived of mast cells but the tumor cells themselves sustain angiogenesis by upregulating angiogenesis factors.
23. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S.et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α cells. Nature. 385:1997;729-733.
24. Moss M.L., Jin S-L.C., Milla M.E., Burkhart W., Carter H.L., Chen W-J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R.et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α Nature. 385:1997;733-736.
25. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., Russell W.E., Castner B.J., Johnson R.S., Fitzner J.N.et al. An essential role for ectodomain shedding in mammalian development. Science. 282:1998;281-284. Analysis of ADAM17/TACE gene knockout mice reveals an extended substrate repertoire for the enzyme, implicating ectodomain shedding by metalloproteinases as a general mechanism regulating autocrine and paracrine signaling of several membrane-bound growth factors.
26. ••] support the notion that host inflammatory components play a significant role in early skin carcinogenesis.
27. Dong J., Opresko L.K., Dempsey P.J., Lauffenburger D.A., Coffey R.J., Wiley H.S. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci USA. 96:1999;6235-6240.
28. Suzuki M., Raab G., Moses M.A., Fernandez C.A., Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 272:1997;31730-31737.
29. Gallea-Robache S., Morand V., Millet S., Bruneau J.M., Bhatnagar N., Chouaib S., Roman-Roman S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine. 9:1997;340-346.
30. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V.et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:1998;39-44.
31. Lombard M.A., Wallace T.L., Kubicek M.F., Petzold G.L., Mitchell M.A., Hendges S.K., Wilks J.W. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res. 58:1998;4001-4017.
32. Christofori G., Semb H. The role of the cell-adhesion molecule E cadherin as a tumor-suppressor gene. Trends Biochem Sci. 24:1999;73-76. A comprehensive review describing that loss of E-Cadherin during the development of most epithelial cancers may not only contribute to loss of cell-cell adhesion, but also convey signals that actively induce tumor cell invasion and metastasis, thus, implicating E-Cadherin as a potential tumor suppressor gene.
33. Perl A-K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:1998;190-193. An elegant study investigating the functional importance of E-Cadherin in a transgenic mouse model of islet carcinogenesis. Re-establishment of intact E-Cadherin complexes results in arrest of tumor development at the benign adenoma stage, whereas expression of a dominant-negative form of E-cadherin induces early invasion and metastasis. These results demonstrate that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from benign adenomas to malignant carcinoma.
34. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M.J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 139:1997;1861-1872.
35. Sternlicht M.D., Bissell M.J., Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000;. in press.
36. Lochter A., Srebrow A., Sympson C.J., Terracio N., Werb Z., Bissell M.J. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem. 272:1997;5007-5015.
37. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J-P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98:1999;137-146. The first in vivo demonstration where over-expression of an extracellular proteinase, stromelysin-1, in the stromal compartment of mammary glands is able to promote spontaneous premalignant changes and malignant conversion to mesenchymal-like tumors. Once inititiated, tumors become independent of stromelysin-1 and show specific genomic changes. These data indicate that stromelysin-1 influences tumor initiation and alters neoplastic risk.
38. Rutter J.L., Mitchell T.I., Butticè G., Meyers J., Gusella J.F., Ozelius L.J., Brinckerhoff C.E. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58:1998;5321-5325. This work raises the issue that the search for cancer susceptibility loci - containing mutations, amplifications, and/or polymorphisms - should expand to include genes encoding extracellular proteinases.
39. D'Armiento J., DiColandrea T., Dalal S.S., Okada T., Huang M.T., Conney A.H., Chada K. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol. 15:1995;5732-5739.
40. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. A novel angiogenesis inhibitor which mediates the suppression of metastasis by a Lewis Lung carcinoma. Cell. 79:1994;315-328.
41. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812. Using transgenic mice, predisposed to de novo islet cell carcinogenesis, as a preclinical testing model, the authors have examined stage-specific efficacy of several potent angiogenesis- and MMP-inhibitors on neoplastic progression. The work clearly demonstrates differential efficacy of tested therapeutics dependent upon neoplastic stage.
42. Dong Z., Kumar R., Yang X., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in lewis lung carcinoma. Cell. 88:1997;801-810.
43. Patterson B.C., Xiang Q., Sang A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem. 272:1997;28823-28825.
44. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 274:1999;29568-29571.
45. O'Reilly M., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
46. Brown P.D. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol. 14:1997;1-10.
47. Pierson R: Bayer ends trial of novel cancer, arthritis drug. http://news.lycos.com/stories/Science/19990926RTSCIENCE-HEALTH-BAYER.asp.
48. Soloway P., Alexander C.M., Werb Z., Jaenisch R. Targeted mutagenesis of TIMP-1 reveals that experimental metastasis is influenced by the TIMP-1 genotype of the tumor but not by that of the host. Oncogene. 13:1996;2307-2314.
49. Coussens L.M., Hanahan D., Arbeit J.M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol. 149:1996;1899-1917.